Abstract:BackgroundHigh-field intraoperative magnetic resonance imaging (iMRI) has been studied in two single-centre randomised trials with patients who have glioblastoma and is hypothesised to enable a greater extent of tumour resection and prolong survival in patients with gliomas. iMRI for glioblastomas has also been shown to be significantly superior to 5-ALA and white-light surgery. However, the real value of iMRI is still a controversial issue. Given that use of this technology is relatively expensive, a high-quality prospective randomised trial is necessary before the approach can be made widely available. We have undertaken a single-centre prospective, randomised controlled trial to assess the clinical efficacy of 3.0T iMRI-guided resection of malignant gliomas compared with conventional neuronavigation only. Here we present the interim analysis of a long-term follow-up of patients with high-grade gliomas.MethodsEligible patients were aged 18–70 years with suspected (as assessed by consaltant surgeon), newly diagnosed malignant supratentorial glioma, met the Karnofsky performance scale 70 or above, and for whom gross total resection was intended. Patients were excluded if they had: tumour of the midline, basal ganglia, cerebellum, or brain stem; MRI contraindications; inability to give informed consent; renal or hepatic insufficiency; history of malignant tumours of other systems; or pathology other than astrocytoma, oligodendroglioma, or oligoastoryctoma (WHO grade II to IV). All participants were randomly assigned to either the trial group (iMRI group) or control group (conventional neuronavigation group) after giving written consent. All surgical protocols including conventional neuro-navigation are identical between the two groups; iMRI is specifically used in the trial group. The estimated sample size was 303 patients in the intent-to-treat analysis to give 80% complete power with a type I error of 0·05. Computational randomisation was done when maximal safe resection was achieved by the masked surgeons. The primary endpoint was extent of tumour resection. The secondary endpoints were progression-free survival and overall survival. This trial is registered with ClinicalTrial.gov, number NCT01479686. This study was approved by the Huashan Institutional Review Board. Written informed consents were given by patients or their attorneys before surgery.FindingsBetween March, 2012, and August, 2015, we enrolled 202 patients, 11 of whom were subsequently excluded because of unbefitting pathology. 177 patients were followed-up more than 6 months and subsequently analysed. 190 patients had low-grade gliomas (51 males vs 39 females, mean age 38·55 years [SD 9·56]), and 87 patients had high-grade gliomas (56 males vs 31 females, mean age 50·42 years [12·18). 43 of the patients with high-grade gliomas were enrolled in the iMRI group, and 44 patients with high-grade gliomas were enrolled in the control group. The extent of tumour resection (iMRI median 100% [IQR 70·87–100] vs control median 98·76% [51·81–100]) and the rate of gross total resection (86% vs 45%) were higher in the iMRI group than that in the control group (p<0·0001). Patients in the iMRI group who had eloquent high-grade gliomas had significantly longer progression-free survival (median not reached vs 13·2 months, p=0·012) and overall survival (median not reached vs 21·5 months, p=0·003) than patients in the control group. No events were identified as side-effects of iMRI.InterpretationThe results address hypotheses about the clinical benefits of 3.0T iMRI-guided maximal safe resection of glioma. It is practical to increase the extent of tumour resection for high-grade gliomas to prolong progression-free survival and overall survival, especially for eloquent high-grade gliomas.FundingNational Key Technology R&D Program of China (No. 2014BAI04B05) and the Shanghai Municipal Health Bureau (XBR2011022).

The Clinical Utility Of Multimodal Mr Image-Guided Needle Biopsy In Cerebral Gliomas

Application of MRS- and ASL-guided navigation for biopsy of intracranial tumors.

Multimodal imaging in cerebral gliomas and its neuropathological correlation

Application Of Magnetic Resonance Spectroscopy In The Preoperative Grading Of Gliomas

Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Combining Amide Proton Transfer-Weighted and Arterial Spin Labeling Imaging to Differentiate Solitary Brain Metastases from Glioblastomas

The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma

Preliminary Application of Magnetic Resonance Spectroscopy Guided Navigation in Needle Biopsy of Intracra-nial Lesions

[Neuroimaging diagnosis and therapeutic efficacy of different surgical methods of gliomatosis cerebri]

3.0T Imri-Guided Resection of Eloquent High-Grade Gliomas: Preliminary Results of A Randomised Controlled Trial

Real-time Image Guided Brain Biopsy Using Low-Field Intraoperative Magnetic Resonance Imaging: Preliminary Clinical Report

Metabolic Approach for Tumor Delineation in Glioma Surgery: 3d Mr Spectroscopy Image-Guided Resection

1H-MR spectroscopy in grading of cerebral glioma: A new view point, MRS image quality assessment

High-Field Imri Guided Resection in Cerebral Glioma Surgery: A Prospective, Randomized, Parallel Controlled Trial

142 3.0T Imri Guided Resection in Cerebral Glioma Surgery

Clinical evaluation of resection of functional area gliomas guided by intraoperative 3.0 T MRI combined with functional MRI navigation

Noninvasive assessment of Ki-67 labeling index in glioma patients based on multi-parameters derived from advanced MR imaging

Noninvasively Evaluating the Grading of Glioma by Multiparametric Magnetic Resonance Imaging

Statistical multiscale mapping of IDH1, MGMT, and microvascular proliferation in human brain tumors from multiparametric MR and spatially-registered core biopsy

Real-time Intraoperative Magnetic Resonance Imaging Guided Glioma Resection:Experience of 158 Cases

Comparison of Diagnostic Accuracy of Magnetic Resonance Spectroscopy with Conventional Magnetic Resonance Imaging for Brain Tumors and Correlation with Histopathology as Gold Standard